莫沙必利+铝碳酸镁咀嚼片联合熊去氧胆酸钠治疗胆汁反流性胃炎疗效观察

Observation on the curative effect of mosapride + hydrotalcite chewable tablets combined with sodium ursodexoxycholate in the treatment of bile reflux gastritis

目的探讨莫沙必利+铝碳酸镁咀嚼片联合熊去氧胆酸钠治疗胆汁反流性胃炎临床疗效。方法将106例胆汁反流性胃炎患者按照随机数字表法分为研究组与对照组,各53例。两组均给予莫沙必利及铝碳酸镁咀嚼片治疗,研究组在此基础上给予熊去氧胆酸钠治疗,观察4周。比较两组临床疗效,比较治疗前后两组血浆胃动素及血管活性肠肽水平,采用反流病诊断问卷及胃食管反流疾病生活质量量表评定两组症状及生活质量,比较两组不良反应发生率。结果研究组治疗总有效率显著高于对照组(P<0.01)。治疗后两组血浆胃动素水平显著高于治疗前(P<0.01),血管活性肠肽水平显著低于治疗前(P<0.01),研究组较对照组变化更显著(P<0.01)。治疗后两组反流病诊断问卷及胃食管反流疾病生活质量量表评分均较治疗前显著降低(P<0.01),研究组显著低于对照组(P<0.01)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论莫沙必利+铝碳酸镁咀嚼片联合熊去氧胆酸钠治疗胆汁反流性胃炎疗效显著,可调节患者血浆胃动素及血管活性肠肽水平,提高生活质量,安全性高。

Objective To investigate the clinical efficacy of mosapride+hydrotalcite chewable tablets combined with sodium ursodexoxycholate in the treatment of bile reflux gastritis.Methods A total of 106 patients with bile reflux gastritis were divided into study group and control group according to random number table method,with 53 cases in each group.Both groups were treated with mosapride and hydrotalcite chewable tablets.On this basis,the study group was treated with sodium ursodexoxycholate for 4 weeks.The clinical efficacy,plasma motilin(MTL)and vasoactive intestinal peptide(VIP)levels of the two groups were compared before and after treatment.Reflux disease questionnaire(RDQ)and gastroesophageal reflux disease-health-related quality of life(GERD-HRQL)were used to assess the symptoms and quality of life of the two groups.The incidence of adverse reactions between the two groups was compared.Results The total effective rate in study group was significantly higher than that in control group(P<0.01).After treatment,the level of MTL in the two groups was significantly higher than that before treatment(P<0.01),and the level of VIP was significantly lower than that before treatment(P<0.01),and the study group changed more significantly than the control group(P<0.01).RDQ and GERD-HRQL scores in the two groups after treatment were significantly lower than those before treatment(P<0.01),and those in the study group were significantly lower than those in the control group(P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Mosapride+hydrotalcite chewable tablets combined with sodium ursodexoxycholate has a significant effect in the treatment of bile reflux gastritis.It can adjust patients'plasma MTL and VIP levels,improve the quality of life,and have high safety.